@kervio thank you for taking the time to explain this in details. A couple of remarks: the trial is powered now with 21 hospitals, up from 15 in August, and has enrolled 50% in mid October. We may hope that 60% enrollment would be achieved in November when the DSMB will come up with the 45% interim analysis. Also, as you pointed out, SOC ensures better results as 65% of ventilated patients decease down from 85% in April, about 20% improvement. I feel this may help not only placebo but maybe also the patients who receive the treatment. If we improve by the same proportion, 20%, we would be closer to 80% than 75% (9/12) survival rate. This in turn affects the differential.
Let’s hope, and be patient
GL all
Overwhelming efficacy - the stats required, page-495
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |